This conclusion is based on a spatial functional genomics screen (Perturb‐map) performed in preclinical ovarian cancer models, which recapitulated tumor heterogeneity and revealed that IL‐4 directs localized TME composition, driving clonal selection and immunotherapy resistance. The gene discussed is IL4; the disease is ovarian cancer.